Prostaglandin E2 receptors as therapeutic targets in renal fibrosis

Henricus A.M. Mutsaers; Rikke Nørregaard

doi:10.23876/j.krcp.21.222

Kidney Res Clin Pract > Volume 41(1); 2022 > Article

Mutsaers and Nørregaard: Prostaglandin E2 receptors as therapeutic targets in renal fibrosis

Review Article

Kidney Research and Clinical Practice 2022;41(1):4-13.

Published online: January 13, 2022

DOI: https://doi.org/10.23876/j.krcp.21.222

Prostaglandin E2 receptors as therapeutic targets in renal fibrosis

Henricus A.M. Mutsaers

, Rikke Nørregaard

Department of Clinical Medicine, Aarhus University, Aarhus, Denmark

Correspondence: Rikke Nørregaard Department of Clinical Medicine, Aarhus University, Palle Juul-Jensens Boulevard 99, DK-8200 Aarhus N, Denmark E-mail: rn@clin.au.dk

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial and No Derivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/) which permits unrestricted non-commercial use, distribution of the material without any modifications, and reproduction in any medium, provided the original works properly cited.

Abstract

Prostaglandin E2 (PGE2), a lipid mediator produced by the cyclooxygenase enzyme system, is the main prostaglandin in the kidney. PGE2 is involved in various physiological and pathophysiological processes in the kidney, including renal hemodynamics, water and salt balance, and renal fibrosis—a key pathological feature of progressive kidney diseases. PGE2 functions by binding to four G-protein-coupled EP receptors (EP1 to EP4), which stimulate different intracellular signaling pathways. The intrarenal distribution of the four EP receptors as well as the different downstream signaling pathways associated with each receptor give rise to the distinct functional consequence of activating each receptor subtype. This review summarizes the current data on the renal expression of the four EP receptors and delineates the role of each receptor in renal fibrosis.

Keywords: Chronic kidney disease, Cyclooxygenase-2, Prostaglandin E2, Renal fibrosis

Introduction

Chronic kidney disease (CKD) affects 8% to 16% of the global population and is the 16th leading cause of years of life lost. CKD incidence and prevalence have been increasing concurrently with increases in lifespan and lifestyle diseases such as diabetes, hypertension, and obesity [1,2]. CKD is defined by the presence of kidney abnormalities, a decline in renal function (glomerular filtration rate [GFR] of <60 mL/min/1.73 m²), or albuminuria for more than 3 months [3]. CKD is characterized by the development of renal fibrosis and progressive loss of renal function, and ultimately CKD leads to end-stage renal disease (ESRD). The main goal of CKD therapy is to hamper progression to ESRD by treating underlying diseases, such as hypertension, diabetes, and albuminuria, and to prevent cardiovascular disease, which is the main cause of morbidity and mortality in CKD patients [4]. However, despite these therapeutic approaches, the absolute risk of renal and cardiovascular morbidity and mortality in the CKD population remains extremely high [5]. Therefore, more effective therapeutic options are needed to effectively halt the progression of renal function loss.

Regardless of the primary cause, renal fibrosis is the hallmark of progressive CKD. Fibrosis is characterized by excessive deposition of extracellular matrix (ECM) proteins by activated myofibroblasts, resulting in loss of organ architecture (scarring) and function [6,7]. Fibrogenesis is initiated in response to chronic kidney damage; following renal injury, profibrotic factors are produced by injured tubular epithelial cells and infiltrating inflammatory cells that stimulate signaling events leading to myofibroblast activation and ECM production [8,9].

Transforming growth factor-β (TGF-β) is one of the key regulators involved in the fibrotic process and, irrespective of etiology, elevated TGF-β levels correlate with increased activity of profibrotic signaling pathways and CKD progression [10,11]. TGF-β can directly promote ECM protein production, including collagen 1 and fibronectin, via the Smad signaling pathway, which is recognized as a major pathway of TGF-β signaling in progressive renal fibrosis [10,12]. Moreover, several studies have demonstrated that TGF-β stimulates expression of cyclooxygenase-2 (COX-2) and the production of its metabolic product prostaglandin E2 (PGE2) in renal cells [13–18], indicating an important role for the COX-2/PGE2 system in renal fibrosis and CKD. The focus of this review is the role of PGE2 in the development and progression of renal fibrosis in CKD. We will particularly highlight PGE2 EP receptors as promising targets for renal fibrosis.

The prostaglandin system

Prostaglandins are important lipid mediators that play critical roles in modulating numerous physiological and pathophysiological actions in different organs. In the kidney, prostaglandins are of major importance for regulating renal hemodynamics, like mediating blood pressure and fluid metabolism [19–21]. Similarly, prostaglandin synthesis can be stimulated in response to different pathophysiological situations, including inflammation, pain, and cancer [22,23]. Prostaglandins are derived from arachidonic acid and are metabolized to the intermediary product prostaglandin G2/prostaglandin H2 (PGG2/PGH2), which is further converted to the bioactive PGE2, prostaglandin I2 (PGI2), prostaglandin D2 (PGD2), prostaglandin F2α (PGF2α), and thromboxane A2 (TXA2) by tissue-specific synthases [24]. These prostaglandins primarily exert their function by binding to specific prostaglandin receptors, with each prostaglandin modulating different cellular biochemical pathways depending on the specific receptor stimulated [25–27]. COX chiefly regulates the production of the five abovementioned prostaglandins by adjusting the substrate (PGG2/PGH2) supply to the individual tissue-specific synthases. The COX enzyme exists in two isoforms; COX-1 and COX-2. We have previously provided an exhaustive review of the role of the COX enzymes in several physiological and pathophysiological processes in the kidney [28].

Prostaglandin E2

PGE2 is the major prostaglandin in the kidney and the role of PGE2 in renal health and disease has been widely studied. PGE2 can be produced by all renal cells via the enzyme PGE2 synthase. Currently, three PGE2 synthases have been cloned, including microsomal prostaglandin E2 synthase (mPGES)-1, mPGES-2, and cytosolic PGES [29]. Among the three PGES isoforms, mPGES-1 has been identified as the most abundant renal PGES. It is highly inducible in response to (patho)physiological stimuli and acts in concert with COX-2 to generate PGE2 [29–31]. The role of mPGES-1 in CKD is complex [32]. In a paper by Jia et al. [33], it was demonstrated that inhibition of mPGES-1 may be a novel therapeutic strategy for improving renal function and urine concentration ability in an experimental model of CKD.

PGE2 can bind to four G-protein-coupled EP receptors (EP1–EP4) that stimulate different intracellular signaling pathways [25–27,34,35]. The COX pathway leading to PGE2 synthesis as well as its downstream receptors are depicted in Fig. 1. These EP receptors are often simultaneously expressed in renal cells and their relative expression levels dictate the overall cellular response to PGE2. The localization of the EP receptors along the nephron is illustrated in Fig. 2.

The EP1 receptor is highly expressed in the collecting duct [36–38], but EP1 is also found in proximal tubules [39], glomerular mesangial cells (MCs) [40], and podocytes [41,42] as well as in thick ascending limbs [43]. Activation of EP1 increases intracellular calcium, thus contributing to the natriuretic and diuretic effects of PGE2 [43-45], as well as playing an important role in the regulation of blood pressure [46]. The EP2 receptor is detected in vascular smooth muscle cells and renal interstitial cells. Additionally, EP2 is also expressed in glomeruli, the descending thin limb of the loop of Henle, and cortical and outer medullary collecting ducts as shown by reverse transcription polymerase chain reaction and functional studies [47–50]. EP2 stimulates adenylate cyclase and signals via the secondary messenger cyclic adenosine monophosphate (cAMP) [26]. In addition, it has been described that EP2 also can signal through β-arrestin-dependent pathways, including extracellular signal-regulated kinase and AKT [51]. The EP3 receptor is mainly expressed in the distal nephron and is most abundant in medullary thick ascending limbs and collecting ducts [52,53]. EP3 exists as different splice variants that define the preference for G-protein coupling [54,55]. It preferentially signals via Gi protein to inhibit adenylate cyclase and thereby decrease cAMP levels. However, EP3 is also involved in the regulation of intracellular calcium levels [26,34] and activation of the G12/G13 pathway, which activates Rho kinase [56]. The EP4 receptor is abundantly expressed in vascular tissue but also found in nearly all renal cell types, including proximal tubules, collecting ducts, thick ascending limb, and distal tubules [39,48]. Like the EP2 receptor, the EP4 receptor signals via Gαs to increase cAMP levels but coupling to Gi and β-arrestin has also been demonstrated [57,58]. The intrarenal distribution of EP receptors, as well as the different downstream signaling pathways, suggest distinct functional consequences of activating each receptor subtype. Next, we will delineate the role of each EP receptor in the development and progression of renal fibrosis. Moreover, the impact of EP receptor modulation on renal fibrosis is summarized in Table 1.

The role of prostaglandin E2 EP receptors in development and progression of renal fibrosis

EP1

In 1999, Ishibashi et al. [40] reported that treatment with SC-51322, a specific EP1 receptor antagonist, dose-dependently reduced high-glucose-induced DNA synthesis in rat MCs. They believed that increased MC proliferation reflected the early stages of glomerulosclerosis; thus, their findings suggested that EP1 receptor antagonism might be beneficial for treating diabetic nephropathy. Three years later, they demonstrated that selective EP1 blockade, using ONO-8713, attenuated nephropathy progression in a rat model of type-1 diabetes [59]. With regard to glomerulosclerosis, they observed that treatment with ONO-8713 markedly reduced glomerular messenger RNA (mRNA) expression of TGF-β1 and fibronectin in diabetic rats [59]. However, despite these promising results, research into the EP1 receptor and diabetes-induced renal fibrosis was virtually absent for a decade. In 2013, Thibodeau et al. [60] studied the onset and progression of diabetic nephropathy in EP1^−/− mice. Their study revealed that absence of the EP1 receptor protected against diabetes-induced renal injury, illustrated in part by a reduction in mesangial matrix deposition and cortical fibronectin expression compared with diabetic mice. Additionally, they showed that treatment with ONO8711 as well as EP1 small interfering RNA (siRNA) completely mitigated PGE2-induced fibronectin expression in mouse proximal tubule cells [39,60]. In line with these results, it has been reported that fibronectin and collagen I expression was lower in TGF-β-exposed EP1^−/− MCs than in wild-type (WT) MCs [17]. The exact molecular mechanisms underlying the protective effects of EP1 antagonism remain unclear; however, it has been postulated that it might be related to a reduction in reactive oxygen species and suppression of endoplasmic reticulum (ER) stress [39,61]. Next to diabetic nephropathy, it has been proposed that the EP1 receptor plays a role in hypertension-related renal injury. Suganami et al. [62] demonstrated, in stroke-prone spontaneously hypertensive rats, that treatment with ONO-8713 for 5 weeks improved renal function and attenuated the development of interstitial fibrosis. Conversely, in mice with long-standing hypertension, it was demonstrated that absence of the EP1 receptor was associated with a reduction in glomerular filtration as well as ultrastructural injury to podocytes and glomerular endothelium [63]. Interestingly, in both studies the impact of EP1 receptor modulation was observed despite persistent hypertension. Recently, Chen et al. [14] reported that antagonizing the EP1 receptor with SC‑19220 improved renal function and fibrosis in mice subjected to 5/6 nephrectomy (PNx), most likely by reducing ER stress. Moreover, they demonstrated that activation of the EP1 receptor with 17‑phenyl‑trinor‑PGE2 ethyl amide aggravated renal injury in PNx mice. Taken together, it appears that EP1 receptor antagonism protects against diabetes- and CKD-induced renal fibrosis. However, its role in hypertensive kidney disease remains unclear.

EP2

Studies regarding the role of the EP2 receptor in renal fibrosis are more recent. In 2018, Liu et al. [64] reported that butaprost, one of the older synthetic EP2 receptor agonists, attenuated TGF-β-induced podocyte injury by promoting cell proliferation and reducing apoptosis. Additionally, Jensen et al. [65] recently demonstrated that butaprost markedly reduced renal fibrosis in mice subjected to unilateral ureteral obstruction (UUO) surgery as assessed by a decrease in fibronectin, α-smooth muscle actin, and collagen 1A1 expression. More importantly, they also demonstrated that butaprost elicited an antifibrotic effect in TGF-β-exposed human precision-cut kidney slices [65]. Thus, their study provided strong evidence that the effect of butaprost may translate to clinical care since its effects on markers of fibrosis are present in UUO mice and human kidney slices [66]. The mechanisms of action underlying the antifibrotic effect of butaprost is not fully understood. Jensen et al. [65] proposed that butaprost had a direct effect on TGF-β/Smad signaling, independent of the cAMP/PKA pathway. Additionally, butaprost might mitigate ER stress [61]. Interestingly, a recent study regarding autosomal dominant polycystic kidney disease (ADPKD), demonstrated that, while EP2 antagonism reduced cyst formation in vitro, treatment of Pkd1^nl/nl mice with PF-04418948, a selective EP2 antagonist, resulted in more severe cystic disease and renal fibrosis [67]. Thus, although evidence is scarce, all of the current studies, including work in human precision-cut kidney slices, support the notion that EP2 receptor activation can mitigate renal fibrogenesis.

EP3

Using single-cell RNA sequencing, Wu et al. [68] demonstrated that the EP3 receptor is highly expressed in myofibroblasts isolated from a human rejected kidney allograft biopsy (http://humphreyslab.com/SingleCell/). This might indicate that the EP3 receptor is involved in myofibroblast activation and/or ECM production. Yet, studies on the role of this receptor in renal fibrogenesis are absent. In a mouse model of nephrotoxic serum-induced nephritis, PGE2 administration restored renal function and mitigated renal damage; however, this positive effect was completely abolished by exposure to the EP3 receptor antagonist L-798106 [69]. Suggesting that EP3 receptor activation might protect against renal injury. Furthermore, EP3 receptor depletion was associated with cardiac fibrosis and reduced MMP-2 expression and activity in mice [70]. In contrast, using gingival fibroblasts, it was demonstrated that EP3 receptor activation increased the gene and protein expression of connective tissue growth factor (CTGF) [71], which could promote fibrogenesis. Clearly, the role of EP3 receptor in fibrosis and its therapeutic potential remain unknown.

EP4

Of all PGE2 receptors, EP4 is most widely studied in the context of renal fibrosis. In 2006, Vukicevic et al. [72] demonstrated in a rat model of mercury chloride (HgCl₂)-induced acute renal failure that treatment with the EP4 agonist, CP-044,519-02, restored renal function (serum creatinine and blood urea nitrogen) and significantly improved histopathological outcomes (proximal tubule necrosis and total number of apoptotic cells). They also reported that EP4 agonism markedly improved GFR in rats subjected to PNx, which was associated with reduced glomerular sclerosis, more viable glomeruli, less tubulointerstitial injury, and better preservation of proximal and distal tubule structure [72]. Six years later, Nakagawa et al. [73], used EP4^–/– mice to further unravel the role of this receptor in renal fibrosis. They demonstrated that UUO-induced tubulointerstitial fibrosis, as assessed by collagen deposition, macrophage infiltration, myofibroblast proliferation and TGF-β1 and CTGF mRNA levels, was more pronounced in the kidneys of knockout mice than WT mice. Moreover, stimulation of the EP4 receptor using ONO-4819 significantly reduced UUO-induced fibrosis in WT mice, but not in EP4^–/– mice, indicating that the positive effect of ONO-4819 on tubulointerstitial fibrosis was mediated by EP4 [73]. Of note, the antifibrotic effect of ONO-4819 was confirmed using another model of kidney disease as well, viz. folic acid-induced nephropathy [73]. They also showed that the EP4 agonist ONO-AE1-329 significantly suppressed platelet‑derived growth factor-BB-induced proliferation of renal fibroblasts isolated from WT kidneys, but not of fibroblasts isolated from EP4^–/– kidneys [73]. Furthermore, ONO-AE1-329 significantly inhibited TGF-β1-induced CTGF production by WT fibroblasts but not by EP4^–/– fibroblasts [73]. This elegant work provided strong evidence that the EP4 receptor is a potent endogenous therapeutic target limiting renal fibrosis [74]. In line with these results, it was demonstrated that treatment with EP4 siRNA slightly increased PGE2-induced fibronectin expression in mouse proximal tubule cells [39]. Additionally, Luo et al. [75] reported that treatment with the EP4 agonist CAY10598 markedly suppressed TGF-β1-induced protein expression of collagen I and fibronectin in murine inner medullary collecting duct cells. They also showed that CAY10598 treatment mitigated angiotensin II-mediated NLRP3 inflammasome activation in human proximal tubule cells. Interestingly, similar to the findings with EP2 receptor modulation, treatment with the EP4 agonist ONO-AE1-329 promoted cyst growth in MDCK II and OX161-C1 cells, whereas EP4 receptor blockade in vivo increased disease severity in two mouse ADPKD models [67]. Taken together, all these studies seem to indicate that EP4 agonism mitigates fibrotic processes in the kidney. However, the role of the EP4 receptor in renal fibrogenesis might not be so clear-cut, as Lannoy et al. [67] already illustrated.

In 2010, it was shown that podocyte-specific EP4 deletion significantly reduced glomerulosclerosis in mice subjected to PNx [76]. A few years later, it was demonstrated that 12 weeks of EP4 agonist ONO-AE1-329 administration exacerbated fibrosis in streptozotocin-induced diabetic mice, as shown by increased collagen deposition and elevated gene and protein expression of various fibrosis markers, including collagen I, fibronectin, and α-smooth muscle actin [77]. Importantly, the same study revealed that the profibrotic effect of EP4 agonism was absent in interleukin-6 knockout animals [77]. In line with these results, it was shown that TGF-β1–induced gene and protein expression of collagen 1 and fibronectin was augmented in EP4-overexpressing mouse MCs, while the response to TGF-β1 was absent in EP4^+/− MCs [16]. Moreover, EP4^+/− mice showed fewer fibrotic lesions following PNx than WT mice [16]. More recently, Mizukami et al. [78] demonstrated that repeated administration of ASP7657, a EP4 receptor antagonist, reduced glomerulosclerosis and interstitial fibrosis in rats subjected to PNx, according to histopathological examination. The beneficial effect of EP4 receptor blockade was also seen in a mouse model of cisplatin-induced kidney damage. In these mice, treatment with the EP4 antagonist grapiprant, a nonsteroidal anti-inflammatory drug widely used in veterinary medicine [79], markedly reduced collagen deposition and α-smooth muscle actin expression associated with cisplatin exposure [80]. Taken together, the EP4 receptor has been the greatest focus of research to develop new renal fibrosis therapies. Unfortunately, despite decades of work, results are conflicting and the therapeutic potential of the EP4 receptor remains unclear.

Conclusion

Although the role of COX-2 and PGE2 in renal (patho)physiology is well established, studies revolving around its receptors and renal fibrosis, which is the most damaging process in CKD development, remain sparse (~20 at the time of writing). Still, the current body of work is enlightening and suggests that PGE2 receptors are potentially important targets for renal fibrosis treatment. Nonetheless, more studies are required to fully unravel the therapeutic potential of PGE2 receptor agonists/antagonists. With the advent of improved translational disease models, such as human precision-cut kidney slices and kidney organoids, pre-clinical studies will provide valuable information on the antifibrotic efficacy of putative therapeutic compounds in human tissue, which will hopefully expedite the development of effective and safe therapeutics that can be used in clinical care.

Notes

Conflict of interest

All authors have no conflicts of interest to declare.

Funding

This work was supported by the Danish Council for Independent Research (grant number 6110-00231B).

Authors’ contributions

Conceptualization: RN

Writing–original draft: HAMM, RN

Writing–review & editing: HAMM, RN

All authors read and approved the final manuscript.

Figure 1.

The cyclooxygenase enzyme system and prostaglandin E2 signaling pathways.

cAMP, cyclic adenosine monophosphate; COX, cyclooxygenase; EPRAP, EP4 receptor-associated protein; ERK, extracellular signal-regulated kinase; IP3, inositol trisphosphate; PGES, prostaglandin E synthase; PGE2, prostaglandin E2; PGG2, prostaglandin G2; PGH2, prostaglandin H2; PI3K, phosphoinositide 3-kinase.

Figure 2.

Renal distribution of the prostaglandin E2 receptors EP1 to EP4.

Table 1.

Impact of PGE2 EP receptor modulation on renal disease

Receptor	Model	Agonist/antagonist	Receptor activity	Overall effect	Reference
EP1	Mesangial cells	SC-51322	-	✓	[40]
	Diabetic nephropathy	ONO-8713	-	✓	[59]
	Diabetic nephropathy	EP1 KO	-	✓	[60]
	Proximal tubule cells	ONO8711	-	✓	[60]
	Proximal tubule cells	EP1 siRNA	-	✓	[39]
	Mesangial cells	EP1 KO	-	✓	[17]
	Hypertension	ONO-8713	-	✓	[62]
	Hypertension	EP1 KO	-	X	[63]
	5/6 Nephrectomy	SC‑19220	-	✓	[14]
	5/6 Nephrectomy	17‑phenyl‑trinor‑PGE2 ethyl amide	+	X	[14]
EP2	Podocytes	Butaprost	+	✓	[64]
	UUO	Butaprost	+	✓	[65]
	hPCKS	Butaprost	+	✓	[65]
	ADPKD	PF-04418948	-	X	[67]
EP3	Nephritis	L-798106	-	X	[69]
EP4	Acute renal failure	CP-044,519-02	+	✓	[72]
	5/6 nephrectomy	CP-044,519-02	+	✓	[72]
	UUO	EP4 KO	-	X	[73]
	UUO	ONO-4819	+	✓	[73]
	Interstitial fibrosis	ONO-4819	+	✓	[73]
	Renal fibroblasts	ONO-AE1-329	+	✓	[73]
	Proximal tubule cells	EP4 siRNA	-	X	[39]
	Inner medullary collecting duct cells	CAY10598	+	✓	[75]
	Proximal tubule cells	CAY10598	+	✓	[75]
	ADPKD	ONO-AE3-208	-	X	[67]
	5/6 nephrectomy	EP4 KO (podocytes)	-	✓	[76]
	Diabetic nephropathy	ONO-AE1-329	+	X	[77]
	Mesangial cells	EP4+	+	X	[16]
	Mesangial cells	EP4 KO	-	✓	[16]
	5/6 nephrectomy	EP4 KO	-	✓	[16]
	5/6 nephrectomy	ASP7657	-	✓	[78]
	Acute kidney injury	Grapiprant	-	✓	[80]

ADPKD, autosomal dominant polycystic kidney disease; hPCKS, human precision-cut kidney slices; UUO, unilateral ureteral obstruction; +, increased; -, decreased; ✓, beneficial; X, detrimental.

References

1. Chen TK, Knicely DH, Grams ME. Chronic kidney disease diagnosis and management: a review. JAMA 2019;322:1294–1304.

2. Jha V, Garcia-Garcia G, Iseki K, et al. Chronic kidney disease: global dimension and perspectives. Lancet 2013;382:260–272.

3. Inker LA, Astor BC, Fox CH, et al. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD. Am J Kidney Dis 2014;63:713–735.

4. Vilayur E, Harris DC. Emerging therapies for chronic kidney disease: what is their role? Nat Rev Nephrol 2009;5:375–383.

5. Lambers Heerspink HJ, de Zeeuw D. Novel drugs and intervention strategies for the treatment of chronic kidney disease. Br J Clin Pharmacol 2013;76:536–550.

6. Genovese F, Manresa AA, Leeming DJ, Karsdal MA, Boor P. The extracellular matrix in the kidney: a source of novel non-invasive biomarkers of kidney fibrosis? Fibrogenesis Tissue Repair 2014;7:4.

7. Liu Y. New insights into epithelial-mesenchymal transition in kidney fibrosis. J Am Soc Nephrol 2010;21:212–222.

8. Liu BC, Tang TT, Lv LL, Lan HY. Renal tubule injury: a driving force toward chronic kidney disease. Kidney Int 2018;93:568–579.

9. Yuan Q, Tan RJ, Liu Y. Myofibroblast in kidney fibrosis: origin, activation, and regulation. Adv Exp Med Biol 2019;1165:253–283.

10. Meng XM, Tang PM, Li J, Lan HY. TGF-β/Smad signaling in renal fibrosis. Front Physiol 2015;6:82.

11. Murakami K, Takemura T, Hino S, Yoshioka K. Urinary transforming growth factor-beta in patients with glomerular diseases. Pediatr Nephrol 1997;11:334–336.

12. Samarakoon R, Overstreet JM, Higgins SP, Higgins PJ. TGF-β1 → SMAD/p53/USF2 → PAI-1 transcriptional axis in ureteral obstruction-induced renal fibrosis. Cell Tissue Res 2012;347:117–128.

13. Xi PP, Xu YY, Chen XL, Fan YP, Wu JH. Role of the prostaglandin E2 receptor agonists in TGF-β1-induced mesangial cell damage. Biosci Rep 2016;36:e00383.

14. Chen X, Yin J, Xu Y, Qiu Z, Liu J, Chen X. Effect of selective inhibition or activation of PGE2 EP1 receptor on glomerulosclerosis. Mol Med Rep 2020;22:2887–2895.

15. Rodríguez-Barbero A, Dorado F, Velasco S, Pandiella A, Banas B, López-Novoa JM. TGF-beta1 induces COX-2 expression and PGE2 synthesis through MAPK and PI3K pathways in human mesangial cells. Kidney Int 2006;70:901–909.

16. Yang GX, Xu YY, Fan YP, et al. A maladaptive role for EP4 receptors in mouse mesangial cells. PLoS One 2014;9:e104091.

17. Chen X, Jiang D, Wang J, et al. Prostaglandin E2 EP1 receptor enhances TGF-β1-induced mesangial cell injury. Int J Mol Med 2015;35:285–293.

18. Li NN, Xu YY, Chen XL, Fan YP, Wu JH. Role of the prostaglandin E2/E-prostanoid 2 receptor signalling pathway in TGFβ-induced mice mesangial cell damage. Biosci Rep 2014;34:e00159.

19. Breyer MD, Harris RC. Cyclooxygenase 2 and the kidney. Curr Opin Nephrol Hypertens 2001;10:89–98.

20. Harris RC, Breyer MD. Physiological regulation of cyclooxygenase-2 in the kidney. Am J Physiol Renal Physiol 2001;281:F1–F11.

21. Hao CM, Breyer MD. Physiological regulation of prostaglandins in the kidney. Annu Rev Physiol 2008;70:357–377.

22. Crofford LJ. COX-1 and COX-2 tissue expression: implications and predictions. J Rheumatol Suppl 1997;49:15–19.

23. Dubois RN, Abramson SB, Crofford L, et al. Cyclooxygenase in biology and disease. FASEB J 1998;12:1063–1073.

24. Funk CD. Prostaglandins and leukotrienes: advances in eicosanoid biology. Science 2001;294:1871–1875.

25. Breyer MD, Breyer RM. Prostaglandin receptors: their role in regulating renal function. Curr Opin Nephrol Hypertens 2000;9:23–29.

26. Breyer MD, Breyer RM. G protein-coupled prostanoid receptors and the kidney. Annu Rev Physiol 2001;63:579–605.

27. Breyer RM, Bagdassarian CK, Myers SA, Breyer MD. Prostanoid receptors: subtypes and signaling. Annu Rev Pharmacol Toxicol 2001;41:661–690.

28. Nørregaard R, Kwon TH, Frøkiær J. Physiology and pathophysiology of cyclooxygenase-2 and prostaglandin E2 in the kidney. Kidney Res Clin Pract 2015;34:194–200.

29. Park JY, Pillinger MH, Abramson SB. Prostaglandin E2 synthesis and secretion: the role of PGE2 synthases. Clin Immunol 2006;119:229–240.

30. Jia Z, Liu G, Downton M, Dong Z, Zhang A, Yang T. mPGES-1 deletion potentiates urine concentrating capability after water deprivation. Am J Physiol Renal Physiol 2012;302:F1005–F1012.

31. Trebino CE, Stock JL, Gibbons CP, et al. Impaired inflammatory and pain responses in mice lacking an inducible prostaglandin E synthase. Proc Natl Acad Sci U S A 2003;100:9044–9049.

32. Regner KR. Dual role of microsomal prostaglandin E synthase 1 in chronic kidney disease. Hypertension 2012;59:12–13.

33. Jia Z, Wang H, Yang T. Microsomal prostaglandin E synthase 1 deletion retards renal disease progression but exacerbates anemia in mice with renal mass reduction. Hypertension 2012;59:122–128.

34. Breyer MD, Breyer RM. Prostaglandin E receptors and the kidney. Am J Physiol Renal Physiol 2000;279:F12–F23.

35. Breyer MD, Zhang Y, Guan YF, Hao CM, Hebert RL, Breyer RM. Regulation of renal function by prostaglandin E receptors. Kidney Int Suppl 1998;67:S88–S94.

36. Morath R, Klein T, Seyberth HW, Nüsing RM. Immunolocalization of the four prostaglandin E2 receptor proteins EP1, EP2, EP3, and EP4 in human kidney. J Am Soc Nephrol 1999;10:1851–1860.

37. Ankorina-Stark I, Haxelmans S, Schlatter E. Receptors for bradykinin and prostaglandin E2 coupled to Ca2+ signalling in rat cortical collecting duct. Cell Calcium 1997;22:269–275.

38. Sugimoto Y, Namba T, Shigemoto R, Negishi M, Ichikawa A, Narumiya S. Distinct cellular localization of mRNAs for three subtypes of prostaglandin E receptor in kidney. Am J Physiol 1994;266(5 Pt 2):F823–F828.

39. Nasrallah R, Hassouneh R, Zimpelmann J, et al. Prostaglandin E2 increases proximal tubule fluid reabsorption, and modulates cultured proximal tubule cell responses via EP1 and EP4 receptors. Lab Invest 2015;95:1044–1055.

40. Ishibashi R, Tanaka I, Kotani M, et al. Roles of prostaglandin E receptors in mesangial cells under high-glucose conditions. Kidney Int 1999;56:589–600.

41. Bek M, Nüsing R, Kowark P, Henger A, Mundel P, Pavenstädt H. Characterization of prostanoid receptors in podocytes. J Am Soc Nephrol 1999;10:2084–2093.

42. Srivastava T, McCarthy ET, Sharma R, et al. Fluid flow shear stress upregulates prostanoid receptor EP2 but not EP4 in murine podocytes. Prostaglandins Other Lipid Mediat 2013;104-105:49–57.

43. Nasrallah R, Zimpelmann J, Eckert D, et al. PGE2 EP1 receptor inhibits vasopressin-dependent water reabsorption and sodium transport in mouse collecting duct. Lab Invest 2018;98:360–370.

44. Hébert RL, Jacobson HR, Fredin D, Breyer MD, et al. Evidence that separate PGE2 receptors modulate water and sodium transport in rabbit cortical collecting duct. Am J Physiol 1993;265(5 Pt 2):F643–F650.

45. Kennedy CR, Xiong H, Rahal S, et al. Urine concentrating defect in prostaglandin EP1-deficient mice. Am J Physiol Renal Physiol 2007;292:F868–F875.

46. Stock JL, Shinjo K, Burkhardt J, et al. The prostaglandin E2 EP1 receptor mediates pain perception and regulates blood pressure. J Clin Invest 2001;107:325–331.

47. Guan Y, Stillman BA, Zhang Y, et al. Cloning and expression of the rabbit prostaglandin EP2 receptor. BMC Pharmacol 2002;2:14.

48. Jensen BL, Stubbe J, Hansen PB, Andreasen D, Skøtt O. Localization of prostaglandin E(2) EP2 and EP4 receptors in the rat kidney. Am J Physiol Renal Physiol 2001;280:F1001–F1009.

49. Olesen ET, Rützler MR, Moeller HB, Praetorius HA, Fenton RA. Vasopressin-independent targeting of aquaporin-2 by selective E-prostanoid receptor agonists alleviates nephrogenic diabetes insipidus. Proc Natl Acad Sci U S A 2011;108:12949–12954.

50. Huang CN, Liu KL, Cheng CH, Lin YS, Lin MJ, Lin TH. PGE2 enhances cytokine-elicited nitric oxide production in mouse cortical collecting duct cells. Nitric Oxide 2005;12:150–158.

51. Chun KS, Lao HC, Langenbach R. The prostaglandin E2 receptor, EP2, stimulates keratinocyte proliferation in mouse skin by G protein-dependent and {beta}-arrestin1-dependent signaling pathways. J Biol Chem 2010;285:39672–39681.

52. Breyer MD, Jacobson HR, Davis LS, Breyer RM. In situ hybridization and localization of mRNA for the rabbit prostaglandin EP3 receptor. Kidney Int 1993;44:1372–1378.

53. Breyer MD, Davis L, Jacobson HR, Breyer RM. Differential localization of prostaglandin E receptor subtypes in human kidney. Am J Physiol 1996;270(5 Pt 2):F912–F918.

54. Schmid A, Thierauch KH, Schleuning WD, Dinter H. Splice variants of the human EP3 receptor for prostaglandin E2. Eur J Biochem 1995;228:23–30.

55. An S, Yang J, So SW, Zeng L, Goetzl EJ. Isoforms of the EP3 subtype of human prostaglandin E2 receptor transduce both intracellular calcium and cAMP signals. Biochemistry 1994;33:14496–14502.

56. Shum WW, Le GY, Jones RL, Gurney AM, Sasaki Y. Involvement of Rho-kinase in contraction of guinea-pig aorta induced by prostanoid EP3 receptor agonists. Br J Pharmacol 2003;139:1449–1461.

57. Regan JW. EP2 and EP4 prostanoid receptor signaling. Life Sci 2003;74:143–153.

58. Fujino H, Regan JW. EP(4) prostanoid receptor coupling to a pertussis toxin-sensitive inhibitory G protein. Mol Pharmacol 2006;69:5–10.

59. Makino H, Tanaka I, Mukoyama M, et al. Prevention of diabetic nephropathy in rats by prostaglandin E receptor EP1-selective antagonist. J Am Soc Nephrol 2002;13:1757–1765.

60. Thibodeau JF, Nasrallah R, Carter A, et al. PTGER1 deletion attenuates renal injury in diabetic mouse models. Am J Pathol 2013;183:1789–1802.

61. Guo NF, Qiu Z, Chen XL, Chen X, Huang JB, Liu J. Prostaglandin E2 receptor subtypes 1 and 2 play a role in TGF-β1-induced renal fibrosis by regulating endoplasmic reticulum stress. Eur Rev Med Pharmacol Sci 2020;24:4954–4962.

62. Suganami T, Mori K, Tanaka I, et al. Role of prostaglandin E receptor EP1 subtype in the development of renal injury in genetically hypertensive rats. Hypertension 2003;42:1183–1190.

63. Nasrallah R, Zimpelmann J, Robertson SJ, et al. Prostaglandin E2 receptor EP1 (PGE2/EP1) deletion promotes glomerular podocyte and endothelial cell injury in hypertensive TTRhRen mice. Lab Invest 2020;100:414–425.

64. Liu J, Zhang YD, Chen XL, et al. The protective effect of the EP2 receptor on TGF-β1 induced podocyte injury via the PI3K / Akt signaling pathway. PLoS One 2018;13:e0197158.

65. Jensen MS, Mutsaers HA, Tingskov SJ, et al. Activation of the prostaglandin E2 EP2 receptor attenuates renal fibrosis in unilateral ureteral obstructed mice and human kidney slices. Acta Physiol (Oxf) 2019;227:e13291.

66. Sands JM. Translating kidney fibrosis: role of the EP2 receptor. Acta Physiol (Oxf) 2019;227:e13318.

67. Lannoy M, Valluru MK, Chang L, et al. The positive effect of selective prostaglandin E2 receptor EP2 and EP4 blockade on cystogenesis in vitro is counteracted by increased kidney inflammation in vivo. Kidney Int 2020;98:404–419.

68. Wu H, Malone AF, Donnelly EL, et al. Single-cell transcriptomics of a human kidney allograft biopsy specimen defines a diverse inflammatory response. J Am Soc Nephrol 2018;29:2069–2080.

69. Kvirkvelia N, McMenamin M, Chaudhary K, Bartoli M, Madaio MP. Prostaglandin E2 promotes cellular recovery from established nephrotoxic serum nephritis in mice, prosurvival, and regenerative effects on glomerular cells. Am J Physiol Renal Physiol 2013;304:F463–F470.

70. Liu S, Ji Y, Yao J, et al. Knockout of the prostaglandin E2 receptor subtype 3 promotes eccentric cardiac hypertrophy and fibrosis in mice. J Cardiovasc Pharmacol Ther 2017;22:71–82.

71. Black SA Jr, Palamakumbura AH, Stan M, Trackman PC. Tissue-specific mechanisms for CCN2/CTGF persistence in fibrotic gingiva: interactions between cAMP and MAPK signaling pathways, and prostaglandin E2-EP3 receptor mediated activation of the c-JUN N-terminal kinase. J Biol Chem 2007;282:15416–15429.

72. Vukicevic S, Simic P, Borovecki F, et al. Role of EP2 and EP4 receptor-selective agonists of prostaglandin E(2) in acute and chronic kidney failure. Kidney Int 2006;70:1099–1106.

73. Nakagawa N, Yuhki K, Kawabe J, et al. The intrinsic prostaglandin E2-EP4 system of the renal tubular epithelium limits the development of tubulointerstitial fibrosis in mice. Kidney Int 2012;82:158–171.

74. Boor P. EP4: a new piece in the fibrotic puzzle. Kidney Int 2012;82:132–135.

75. Luo R, Kakizoe Y, Wang F, et al. Deficiency of mPGES-1 exacerbates renal fibrosis and inflammation in mice with unilateral ureteral obstruction. Am J Physiol Renal Physiol 2017;312:F121–F133.

76. Stitt-Cavanagh EM, Faour WH, Takami K, et al. A maladaptive role for EP4 receptors in podocytes. J Am Soc Nephrol 2010;21:1678–1690.

77. Mohamed R, Jayakumar C, Ramesh G. Chronic administration of EP4-selective agonist exacerbates albuminuria and fibrosis of the kidney in streptozotocin-induced diabetic mice through IL-6. Lab Invest 2013;93:933–945.

78. Mizukami K, Yoshida H, Nozawa E, Wada K, Ugawa T. Renoprotective effects of the novel prostaglandin EP4 receptor-selective antagonist ASP7657 in 5/6 nephrectomized chronic kidney disease rats. Naunyn Schmiedebergs Arch Pharmacol 2019;392:451–459.

79. Kirkby Shaw K, Rausch-Derra LC, Rhodes L. Grapiprant: an EP4 prostaglandin receptor antagonist and novel therapy for pain and inflammation. Vet Med Sci 2015;2:3–9.

80. Abouelkheir M, Shabaan DA, Shahien MA. Delayed blockage of prostaglandin EP4 receptors can reduce dedifferentiation, epithelial-to-mesenchymal transition and fibrosis following acute kidney injury. Clin Exp Pharmacol Physiol 2021;48:791–800.